Response: Commentary: Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
2024

Response to Commentary on Azathioprine in Graves' Disease

Sample size: 270 Commentary Evidence: moderate

Author Information

Author(s): Allam Magdy Mohamed, Ghazy Ramy Mohamed, Elzawawy Hanaa Tarek Hussein

Primary Institution: Alexandria University Student Hospital

Hypothesis

Does azathioprine improve remission rates in patients with severe Graves' disease?

Conclusion

Azathioprine significantly improves remission rates and reduces relapse in patients with severe Graves' disease.

Supporting Evidence

  • Azathioprine improved remission rates from 33.4% to 87.5%.
  • The study included 270 patients with severe Graves' disease.
  • Participants were monitored for 12 months after stopping medication.

Takeaway

This study shows that a medicine called azathioprine can help people with a serious thyroid problem feel better and stay better for longer.

Methodology

Participants were randomly allocated into three groups receiving different doses of azathioprine along with conventional therapy.

Potential Biases

The open-label design could introduce potential bias.

Limitations

The study's open-label design and relatively small sample size may limit the generalizability of the results.

Participant Demographics

Participants were aged 30-65 years, with a gender distribution of 60% female in the azathioprine group.

Statistical Information

P-Value

0.002

Statistical Significance

p = 0.002

Digital Object Identifier (DOI)

10.3389/fendo.2024.1473224

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication